MYGN financials
Myriad Genetics (MYGN) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
MYGN income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $824.50M | $576.60M | -$67.80M | -$365.90M | -3.96 |
| 2024 | $837.60M | $585.40M | -$88.00M | -$127.30M | -1.41 |
| 2023 | $753.20M | $517.00M | -$144.60M | -$263.30M | -3.18 |
| 2022 | $678.40M | $476.40M | -$123.70M | -$112.00M | -1.39 |
| 2021 | $690.60M | $493.00M | -$190.50M | -$27.20M | -0.35 |
| 2020 | $557.00M | $378.80M | -$194.80M | -$223.70M | -2.99 |
- MYGN revenue was $824.50M in fiscal 2025, net income -$365.90M.
Updated 2026-11-05 12:51 UTC